Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI<sup>®</sup> induces enhanced serological, cellular and protective immune responses.

Drug Deliv · 2018 · PMC6058713 · PMID 29542358

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

H5N1 vaccine with formulations slightly increased the IFN-γ production among CD8 T cells, but the change did not reach statistical significance ( Figure 2(A) and Supplementary Figure S1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.